Jade Biosciences (JBIO) reported second-quarter 2026 financial results and a corporate update, including a net loss of $55.8 million for the quarter ended June 30, compared with $32.1 million a year earlier. The company had cash, cash equivalents and investments of $461.2 million as of June 30, 2026, and said its expected runway extends into the fourth quarter of 2028.
The clinical-stage biotechnology company said Phase 2 testing of JADE101 in IgA nephropathy is underway, with interim data expected in 2027, and a Phase 3 registrational trial is expected to begin in the first half of 2027. Jade also began dosing participants with rheumatoid arthritis in a Phase 1 trial of JADE201 and unveiled JADE301 for dermatomyositis.
- R&D expenses $50.1 million in Q2 2026, including $10.6 million in stock-based compensation.
- G&A expenses $8.9 million in Q2 2026, including $3.0 million in stock-based compensation.
- JADE101 Interim Phase 1 data included approximately 70% mean IgA reductions from baseline after a single 700 mg dose.
- JADE301 A Phase 1 healthy volunteer trial is expected to begin in the fourth quarter of 2026, with interim data anticipated in the second half of 2027.
- Capital Jade completed a $172.5 million public offering.
$JBIO Hedge Fund Activity
We have seen 64 institutional investors add shares of $JBIO stock to their portfolio, and 42 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STATE STREET CORP added 1,679,595 shares (+256.2%) to their portfolio in Q2 2026, for an estimated $37,320,600
- RTW INVESTMENTS, LP removed 876,068 shares (-60.4%) from their portfolio in Q1 2026, for an estimated $12,308,755
- ACORN CAPITAL ADVISORS, LLC added 786,760 shares (+inf%) to their portfolio in Q1 2026, for an estimated $11,053,978
- PICTET ASSET MANAGEMENT HOLDING SA added 733,768 shares (+inf%) to their portfolio in Q2 2026, for an estimated $16,304,324
- BLACKROCK, INC. added 487,502 shares (+21.1%) to their portfolio in Q2 2026, for an estimated $10,832,294
- BALYASNY ASSET MANAGEMENT L.P. added 402,489 shares (+inf%) to their portfolio in Q1 2026, for an estimated $5,654,970
- WALLEYE CAPITAL LLC added 365,272 shares (+inf%) to their portfolio in Q2 2026, for an estimated $8,116,343
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
